Bazell Carol, Alston Maggie, Feigler Norbert, Germack Hayley D, Leary Stephanie, Fopalan Winston, Mannino David
Milliman, Inc., New York, New York, United States.
US Medical Respiratory, BioPharmaceuticals, AstraZeneca, Wilmington, Delaware, United Staes.
Chronic Obstr Pulm Dis. 2025 Mar 27;12(2):158-174. doi: 10.15326/jcopdf.2024.0560.
Chronic obstructive pulmonary disease (COPD) poses a substantial burden on individuals and the U.S. health care system. Up-to-date information describing individuals with COPD and their acute hospital-based health care utilization at the state level and by insurance type is lacking.
Individuals with COPD aged 40 and older were identified from large databases of Medicare fee-for-service, Medicaid, and commercial health insurance claims, and counts were extrapolated to the U.S. health insurance market. Demographics and outcome metrics were quantified between January 1 and December 31, 2021, and summarized by state and insurance type.
Approximately 11.7 million insured individuals had COPD in 2021. The largest share were covered by Medicare (79.4%), followed by commercial insurance (11.3%) and Medicaid (9.3%). COPD prevalence varied among states, ranging from 44 (Utah) to 143 (West Virginia) per 1000 insured individuals. Nationwide, annual all-cause mortality for individuals with COPD covered by Medicare (11.5%) was more than double that of Medicaid (5.1%). There were 1.8 million COPD-related acute inpatient hospitalizations nationwide, with the largest share among individuals covered by Medicare (86.4%), followed by Medicaid (9.0%) and commercial insurance (4.6%). COPD-related hospitalization rates also varied among states, ranging from 97 (Idaho) to 200 (District of Columbia) per 1000 individuals with COPD. There were 1.4 million COPD-related emergency department/observation encounters not resulting in acute inpatient admissions nationwide.
There is substantial state and payer variation in COPD prevalence and burden. Understanding this variation provides valuable insights into populations with unmet needs that can inform public health strategies to address gaps.
慢性阻塞性肺疾病(COPD)给个人和美国医疗保健系统带来了沉重负担。目前缺乏关于COPD患者及其在州层面和按保险类型划分的急性住院医疗保健利用情况的最新信息。
从医疗保险按服务收费、医疗补助和商业健康保险理赔的大型数据库中识别出年龄在40岁及以上的COPD患者,并将统计数据推算至美国健康保险市场。在2021年1月1日至12月31日期间对人口统计学和结果指标进行量化,并按州和保险类型进行汇总。
2021年约有1170万参保个体患有COPD。其中最大份额由医疗保险覆盖(79.4%),其次是商业保险(11.3%)和医疗补助(9.3%)。COPD患病率在各州之间有所不同,每1000名参保个体中,患病率从44(犹他州)到143(西弗吉尼亚州)不等。在全国范围内,医疗保险覆盖的COPD患者的年度全因死亡率(11.5%)是医疗补助覆盖患者(5.1%)的两倍多。全国范围内有180万例与COPD相关的急性住院治疗,其中最大份额是医疗保险覆盖的个体(86.4%),其次是医疗补助(9.0%)和商业保险(4.6%)。与COPD相关的住院率在各州之间也有所不同,每1000名COPD患者中,住院率从97(爱达荷州)到200(哥伦比亚特区)不等。全国范围内有140万例与COPD相关的急诊科/观察室就诊未导致急性住院。
COPD的患病率和负担在州和付款人之间存在很大差异。了解这种差异可为未满足需求的人群提供有价值的见解,从而为解决差距的公共卫生策略提供信息。